CINJALL: Treatment for Children With Acute Lymphocytic Leukemia

Completed · Phase 2

Conditions studied: Acute Lymphocytic Leukemia

In brief

The purpose of this research study is to identify better ways to treat children and young adults with acute lymphocytic leukemia (ALL). At the same time, doctors hope to define methods to identify those patients at higher risk for certain side effects, as well as those who are at higher risk for relapse of their leukemia.

Key facts

Study ID

NCT00176462

Run by

Rutgers, The State University of New Jersey

People needed

60

Starts

2001-02-01

Expected to finish

2008-09-01

Last updated by the study team

2014-06-09

Who can join

Age: 1 and older, up to 30. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Patients with medical, psychological, or psychiatric problems that are likely to compromise their ability to tolerate intensive therapy will be ineligible.
• All patients with evidence of significant organ dysfunction not thought to be attributable to ALL (patients with clinically significant congestive heart failure, cardiac ejection fraction <40%, total bilirubin >2, serum creatinine >2) will be ineligible. Note: echocardiogram or MUGA are required prior to therapy ONLY for those patients with history or physical findings suggestive of cardiac dysfunction not directly attributable to anemia or ALL. Note: Patients with total bilirubin >2 but direct (conjugated) bilirubin less than the upper limit of normal will still be eligible. These patients should be evaluated for deficiency of the enzyme glucuronyl transferase.

Where it is running

• Jersey Shore University Medical Center — Neptune City, New Jersey, United States
• Cancer Institute of New Jersey — New Brunswick, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.